newsfilter
← Latest News
PR Newswire·

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...